上海交大附属胸科医院陆舜:肠道菌群或影响PD-1单抗治疗NSCLC的效果
创作:aluba 审核:aluba 2019年05月15日
  • 纳入37名接受纳武单抗治疗的晚期非小细胞肺癌患者,收集各个时期的粪便样本以分析肠道菌群;
  • 将患者分为对纳武单抗治疗应答或不应答的2组;
  • 在治疗开始时,应答组患者的肠道菌群多样性显著高于不应答组,在治疗期间,应答组患者的肠道菌群组成稳定性显著高于不应答组;
  • 肠道菌群多样性更高的患者,其无进展生存期显著长于肠道菌群多样性较低的患者,且其外周血中有着更高比例的可响应PD-1单抗治疗的记忆性CD8+ T细胞及NK细胞亚群。
主编推荐语
aluba
来自上海交通大学附属胸科医院的陆舜团队在Journal of Thoracic Oncology上发表的一项最新研究,发现在接受PD-1单抗治疗的中国非小细胞肺癌患者中,对治疗产生应答的患者的肠道菌群组成及多样性均与不应答的患者有显著差异。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

肠道菌群多样性与中国非小细胞肺癌患者对PD-1单抗治疗的应答相关

10.1016/j.jtho.2019.04.007

2019-04-23, Article

Abstract & Authors:展开

Abstract:收起
PURPOSE: Gut microbiome affecting the responses to immune checkpoint inhibitors (ICIs) against advanced non-small cell lung cancer (NSCLC) has been investigated in western population. However, considering preexisting genetic and gut microbiota variation, the relevance remains unknown in east-Asian NSCLC population. The study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese NSCLC patients treated with an anti-PD-1 blockade.
METHODS: 37 advanced NSCLC patients receiving the treatment of nivolumab were enrolled in the study from the clinical trials CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, every time point receiving nivolumab as well as clinical evaluation and that with disease progression. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multi-color flow cytometry in parallel.
RESULTS: When subgrouping patients into responder (R) and non-responder (NR) according to the clinical response assessed by RECIST1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival (PFS) when compared to those with low diversity. Compositional difference was observed between two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, Prevotella copri in R whereas Ruminococcus_unclassified in NR. Analysis of systemic immune responses using multi-color flow cytometry revealed that patients with high abundance of microbiome diversity in the gut had more frequencies of unique memory CD8 T cell and NK cell subsets in the periphery in response to anti-PD-1 therapy.
CONCLUSIONS: Our results reveal strong correlation between gut microbiome diversity and the responses to anti-PD-1 immunotherapy in Chinese advanced NSCLC patients. Patients with favorable gut microbiome (such as high diversity) exhibit enhanced memory T cell and NK cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti-PD-1 immunotherapy against NSCLC in Chinese population.

First Authors:
Yueping Jin,Hui Dong,Liliang Xia,Yi Yang

Correspondence Authors:
Shun Lu

All Authors:
Yueping Jin,Hui Dong,Liliang Xia,Yi Yang,Yongqiang Zhu,Yan Shen,Huajun Zheng,Chengcheng Yao,Ying Wang,Shun Lu

图片
Journal of Thoracic Oncology期刊

The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients — the Benefits of Diversity

Eric H. Bernicker, Eamonn M.M. Quigley

点评:Journal of Thoracic Oncology同期配发的解读评论文章。

评论